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Last month we brought you reports on
immunology and new treatments from the 6th
Conference on Retroviruses and Opportunistic
Infections. This month we continue our synop-
sis with reports on HIV care utilization, viral
load monitoring, and warnings about new
clades and drug resistant HIV isolates.
• HIV Care Utilization 
Dr. Sam Bozzette presented his data from a
national consortium of HIV providers (1). The
HIV Cost and Services Utilization Study
(HCSUS) (2), described the impact of HIV care
on health, and the cost of that care in the "out-
side world". Delivery of care "outside" may
directly impact correctional HIV care due to its
effect on the health of HIV infected inmates
arriving in correctional facilities. 
Bozzette used information published by the
New York State Department of Correctional
Services (NYSDOCS) on the reduction in HIV-
related mortality to illustrate his first point:
HAART has had an impressive impact on
AIDS mortality (see graph, pg. 5) (3). To sup-
port this point, he referenced three other stud-
ies that describe how HIV morbidity and mor-
tality rates have been reduced when good HIV
care, expert consultation, and HAART have
been made available to patients. One study
showed that hospitals "experienced" in HIV
care had a 21% lower death rate for
Pneumocystis Carinii Pneumonia(PCP) than
hospitals that were less experienced (4).  A
second study showed that HIV infected
patients in the care of experienced providers
had a 31% lower AIDSmortality rate than
patients in the care of other providers (5). A
third study proved that patients in clinics with
more than two HIV "services" had a 36% lower
adjusted odds of developing PCP than those in
clinics with one or none (6). 
• AIDS Cases Decreasing with HAART
Bozzette reported some dramatic facts
gleaned from studies of the large cohort of
3,072 HIV infected patients followed by the
HCSUS HIV providers. He and his collabora-
tors found that the proportion of persons living
with T cell counts less than 200 has decreased
nationally from 35% to 17% between 1996 and
1998.  The number of persons with CD4 T cells
above 200 has increased, suggesting that
HAART is "arresting" the national rate of pro-
gression to AIDS. These researchers extrapo-
lated from their study sample to estimate that
about 335,000 persons attended HIV clinics in
the past year, representing only about half of
the 600,000 to 900,000 persons thought to be
currently living with HIV, according to the CDC (7). 
The HCSUS group found that the distribution
of HIV patients in care was skewed towards
lower CD4 T cell counts. This suggests that
most of the patients who are not in care are in
the early stages of HIV. Bozzette raised con-
cern about identifying these individuals and
getting them into treatment, since, for some
patients, the best time to begin treatment to
prevent the advancement of HIV disease may
be during the early stages of infection.
• Access to HIV Specialty Care
Not all of the patients in Bozzette's study
received specialty care in HIV clinics. While
50% of patients obtained care in HIV specialty
clinic settings, another 23% used emergency
rooms as one of their primary sources of health
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Update from the 6th Conference on 
Retroviruses and Opportunistic Infections
Chicago, Illinois, Jan 31-Feb 3 1999 - Part Two
HEPP News, a forum for correctional prob-
lem solving, evolved out of ongoing discus-
sions among HIV specialists based at the
Brown University AIDS Program about the
need for HIV updates designed for practitioners
in the correctional setting. The board of editors
includes national and regional correctional pro-
fessionals, selected on the basis of their expe-
rience with HIV care in the correctional envi-
ronment and their familiarity with current HIV
treatment. HEPP News targets correctional
administrators and HIV/AIDS care providers
including physicians, nurses, outreach workers
and case managers. Published monthly and
distributed by fax, HEPP News provides up-to-
the-moment information on HIV treatment, effi-
cient approaches to administering such treat-
ments in the correctional environment, national
and international news related to HIV in prisons
and jails, and correctional trends that impact
HIV treatment. Continuing Medical Education
credits are provided by the Brown University
Office of Continuing Medical Education to
physicians who accurately respond to the
questions on the last page of the newsletter;
please see last page for details.
The editorial board and contributors to
HEPP News are well aware of the critical role
prisons and jails play in the treatment and pre-
vention of HIV. The goal of HEPP News is to
provide reports of effective and cost-conscious
HIV care that can truly be implemented within
the correctional environment. We hope this
newsletter achieves that goal.
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Dear Colleagues,
It is my pleasure to be the guest editor for this month's issue of HEPP. This issue is particularly relevant to my work, as it includes a spotlight
on the New York State Department of Correctional Services (NYSDOCS).  We, at the NYSDOCS, provide care for approximately 8,700
inmates living with HIV. Based on information provided in this issue, that number is equivalent to almost 3% of the number of HIV patients
under care in the United States! 
Other topics this month include (in this month's continuation of the 6th Conference on Retroviruses and Opportunistic Infections summary)
HIV care cost and utilization; HIV infection among blood donors, and gender differences in viral load measurements. The author, colleague
and HEPP co-editor Anne De Groot, also discusses the relevance of these issues to health care in the correctional setting.In keeping with
HEPP News' dedication to providing practical information on HIV management for the correctional setting, the HEPPigram this month reviews
viral load measurements. This month's HIV 101 topic is routine immunizations for HIV infected patients. Finally, Dr. Sharee Starrett of New
Jersey Correctional Medical Services contributes a "front line" perspective on managing CMV in the "ask the experts" section.
After reading this issue, readers should be able to recognize meaningful changes in HIV viral load, name several possible approaches to man-
aging CMV, recognize possible differences in viral load by gender, and understand the impact of new treatment approaches on the cost and
utilization of HIV care in outpatient settings.
Next month we will feature a report on HIV infection among incarcerated women, written by Dr. Kathryn Anastos of New York, Dr. Anne De
Groot, and Betsy Stubblefield. That issue will include a spotlight on Pam Dole, a specialist in the gynecological examination of sexually trau-
matized women. As many incarcerated women are victims of some form of sexual abuse (see this month's news flashes), this topic is
extremely relevant to correctional HIV care.  
Thank you for your interest in HEPP News and your continuing support for improving the health care of inmates.  Please take a moment to
write the editors back. Tell us whether HEPP News is works for you and how it might be improved. 
Sincerely,
Lester Wright
Associate Commissioner/Chief Medical Officer
New York State Department of Correctional Services
L E T T E R F R O M T H E E D I T O R
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National HIV Prevention Conference
August 29-September 1, 1999 
Hyatt Regency Atlanta Hotel, Atlanta GA.
Sponsored in part by:The National Minority AIDS Council, American Social
Health Organization (ASHA), the Centers for Disease Control (CDC), The
National Association of People With AIDS (NAPWA)
Register: by July 23, 1999, or after July 23 on site.
Contact:The National Minority AIDS Council, attn: NHPC, 1931 13th
Street, NW, Washington DC 20009-4432
Phone: 404.639.1942   e-mail: 99hivconf@cdc.gov
10th Annual HIV-Meeting the Challenge Conference
May 18, 1999
Fairfax, VA,
Sponsors:Northern Virginia HIV Resource & Consultation Center; Inova
HIV Services.
Contacts: Jacqueline Morgan, Inova HIV Services, 
2832 Juniper St, Fairfax, VA 22031, 
tel: (703) 204-3787, 
email:jacqueline.morgan@inova.com.
S a v e  T h e  D a t e s
care. Perhaps as a result, 30% of those with
a CD4 count less than 200 were not on PCP
prophylaxis (1). Many measures of HIV care
utilization differed by race and ethnicity.
Compared to non-Hispanic whites, Hispanics
and Blacks had fewer clinic visits, more IDU
use, less ART, less PI, and less PCP pro-
phylaxis. Access to HAART was also linked
to race, income, active drug use, gender, risk
behavior, geography, attitudes and beliefs
about HIV care, and whether the HIV care
provider for the patient focused primarily on
HIV care or was involved in other aspects of
health care. These findings  come as no sur-
prise to the correctional HIV provider.
Providing HIV specialty care and related
services in the correctional environment is
one means of improving access to HIV treat-
ment for these under-served populations. 
Adherence in the HCSUS study population
was fairly poor: 57% of patients reported that
they were adherent 7 days a week, 19%
reported that they were adherent 6 days a
week (1). These self-reports may also over
estimate actual adherence, raising grave
concerns about the evolution of drug resist-
ant virus in the HIV-infected patient popula-
tion at large.
• How Much Does HIV Care Cost?
Bozzette and colleagues estimated that there
were 2 million outpatient visits, 100,000
Emergency Room (ER) visits,  900,000 hos-
pital days and 85,000,000 days of antiretrovi-
ral therapy in the first six months of 1996 (1).
The cost of this HIV care was about $6.7 bil-
lion per year, which was less than 1% of the
total US expenditure on health care during
1997 (1). In contrast, HIV-AIDS was the
cause of 7% of total lives lost during the same
year.
Bozzette also evaluated the impact of
HAART on total HIV care costs. Most of the
cost of treating HIV/AIDS in his cohort relat-
ed to pharmaceutical expenditures. He found
that drug expenditures and clinic visits have
increased, but ER visits and hospitalization
have decreased, and the total cost of caring
for HIV/AIDS patients was no different after
these adjustments. During a post-presenta-
tion interview, Bozzette indicated that similar
figures for the impact of HAART in the cor-
rectional setting were not available. 
The good news for correctional healthcare
providers who manage HIV patients is that
there has been a slight decrease in HIV care
costs and improvement in service utilization
from 1996 up until now. That means that
more of our patients will have been tested
and treated with HAART before they arrive at
a correctional setting. The bad news is that
the number of patients who adhere to their
regimens is much less than would be desir-
able. The most important impact of new HIV
treatments has been on mortality; death
rates have dropped dramatically. Setting
aside tangible financial benefits, the intangi-
ble emotional benefits of HAART are palpa-
ble both inside and outside corrections. 
• HIV Infection in US Blood Donors 
Full time blood donors are screened for HIV-
risk behaviors; blood is also screened for evi-
dence of HIV infection before use.
Information from blood-donor screenings
was presented by the CDC (10) giving a
novel perspective on the actual incidence of
HIV infection among a group of individuals
who do not consider themselves at risk. The
relevance of this topic to corrections is that it
expands the ability to identify HIV infected
persons who may not have reported stan-
dard "HIV risks.”
The average rate of acquisition of HIV infec-
tion among full time US blood donors was 8
per 100,000 person years, much lower than
among higher risk groups (10). Studies have
found, however, a higher prevalence of HIV
than the donors may have expected.
Persons in Southeastern states (20-26 new
infections per 100,000), persons of color (25-
30 fold higher HIV incidence rate than
whites), and persons in the 22 to 45 age
range who do not consider themselves to be
HIV infected (2 fold higher than persons
older or younger than that age group) may
have a higher risk of HIV infection than pre-
viously thought.
• New Strains of HIV
In a substudy of 31 recently infected blood
donors,  researchers found evidence, in one
patient, of acquisition of a clade A virus. All of
the other new infections appeared to cluster
with B strains. This report of a non-clade B
virus (the usual strain of virus transmitted in
the US) suggests that the US is not immune
to invasion of other strains of HIV that domi-
nate the epidemic in other parts of the world.
The most important finding in this study is
related to drug resistance: 18 out of the 31
infections among blood donors had changes
related to drug resistance. Resistance to pro-
tease inhibitors predominated. The take-
home message for corrections was that drug
resistance can be  widespread in "free world"
populations. Therefore, patients on HAART
should be monitored for response to treat-
ments and intensification of regimens should
be considered if response is inadequate. As
discussed in the last issue of HEPP News,
viral resistance testing (genotypic anti-retro-
viral resistance testing, or GART) is a tool
The 6th Conference on Retroviruses and Opportunistic Infections
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The "Inside" View: Extrapolating HCSUS Data to Corrections
Bozzette's data are relevant to correctional HIV care providers because they give us a rough estimate of the proportion of the national HIV infected pop-
ulation that is under our care. The National Bureau of Justice Statistics (BJS) recently estimated that there are 35,000 to 47,000 patients with HIV infec-
tion in the nation's prisons and jails (8). Comparing this figure to Bozzette's estimates, prisons and jails are providing care for approximately one tenth of
the total number of HIV infected individuals that are accessing health care.
The HCSUS study also permits some budgetary contrasts. Allowing for some differences in budget estimates, current expenditures on HIV care in cor-
rectional settings may be in the same range as expenditures in the "free world". These estimates run counter to public sentiment that "too much money"
is spent on correctional HIV care.
For example, recent estimates of HIV/AIDS related expenditures reported by the New York State Department of Correctional Services (NYSDOCS) were
$10.8 million directly spent on medical services, and 45.8 million on AIDS programs for approximately 3,000 inmates that are currently accessing HIV care
in the NYSDOCS (9). The Florida State DOC reported spending $19 million in 1998 on HIV medications alone for approximately 2,100 HIV infected
patients.
Just as Bozzette observed for his community patients, HIV infected patients in the correctional setting seem to be unwilling or unable to access HIV care:
less than 50% of the estimated 7,500 to 8,500 HIV infected individuals in the NYSDOCS population are participating in clinical care (10). While some of
these HIV infected individuals may be avoiding HIV care because they are not yet personally "ready" or willing to participate in HIV treatment, some indi-
viduals may be actively avoiding HIV care because of the nature of the correctional setting.
Since we now know that early intervention can preserve immune function and reduce morbidity, efforts to identify HIV infected patients and encourage
them to participate in HIV care inside the correctional environment are critically important. Some methods that are believed to increase inmate participa-
tion in HIV care include: peer education, provider and correctional officer education on HIV risk factors (critical pathways), multiple opportunities to access
HIV testing, confidential test results, improving HIV care quality, and reducing barriers to accessing HIV care.
Due to the concentration of individuals who have HIV infection or are at risk of HIV infection in correctional settings, correctional providers have a unique
opportunity to get at-risk individuals tested and engaged in treatment.
that expands our ability to make better-
informed decisions on treatment (For more
information see the March HEPP News
archives at www.hivcorrections.org). 
• Variations in Viral Load by Gender: Men 
Dr. R.Lyles presented information on the "nat-
ural" progression of viral load in a subset of
270 men enrolled in a large study called the
Multicenter AIDS Cohort Study (MACS)(11).
This cohort has been described in detail in
previous publications (12).  For this report, Dr.
Lyles and co-workers stratified the patients by
viral load and examined progression to AIDS.
Patients who had lower viral load (less than
10,000 copies/ml) at the outset of the study,
had slower progression to AIDS than patients
who had a higher viral load (averaging around
100,000 copies) at the outset (progressing to
AIDS within the first three years). Patients
who did not progress to AIDS within 7 years
of the first viral load had no change in the viral
load over time; and those who were  AIDS
free after 9 years or more had a slight
decrease in the MRNA level over time.  Dr.
Lyles provided data showing that progression
to AIDS could be extrapolated given data
points covering about 1.5 years. 
It is important to emphasize that much of the
data derived from the MACS cohort was
derived prior to the widespread use of
HAART. When questioned about the impact
of HAART on these results, the researchers
suggested that the impact of access to care,
treatment, and adherence was summarized in
the viral load measurements, and therefore
felt that their results were still accurate.
• Women Progress at Lower Viral Loads
Dr. Kathryn Anastos and co-workers com-
pared patients enrolled in the Women's
Interagency HIV Study (WIHS) and MACS (a 
similar study of men) (13). They evaluated the
HIV RNA levels of women in WIHS who had
not initiated ART at the beginning of therapy,
and contrasted their viral loads to a compara-
ble subset of men in the MACS cohort.
In the final analysis, the HIV RNA among
women in this study was 20% lower than the
viral burdens in men with the same CD4 T cell
count who were enrolled in the MACS. After
adjustments for age and racial differences in
the cohort, Dr. Anastos found that the viral
load at which equivalent rates of progression
to AIDS occurred was as much as 35% lower
for women than the rates  observed for men.
If anything, these estimates, according to Dr.
Anastos, underestimate the true differences
between women and men. In response to a
question from the audience, she replied that
we don't know, as of yet, whether we should
initiate HAART at lower viral loads for women
than for men. She suggested that a con-
trolled, prospective study of gender differ-
ences in viral loads would allow researchers
to better control for confounding factors, such
as access to health care and adherence. 
• Need for More Correctional Studies
The lack of reports directly related to correc-
tional HIV care at the Retrovirus Conference
reflected a disconcerting lack of interest by
academic researchers about the impact of
HIV on inmates. Since as many as 10% of the
nation’s HIV infected population may be
accessing care in a correctional setting, it
seems appropriate for a shift in focus. One
means to accomplish this might be for correc-
tional HIV providers to conduct clinical studies
in their facilities, and to submit their reports to
national meetings. 
For information on submitting research to the
7th Conference on Retroviruses and
Opportunistic Infections, contact the
Retrovirus Conference Secretary at
703/684.4876.  Abstracts available at the con-
ference website at http://www.retroconfer-
ence.org/99/
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HEPPigram
A feature of HEPP news providing concise solutions to correctional HIV-related problems
Viral Load Measurements
This table is useful for monitoring the success or failure of
HIV medication.  These numbers are expressed in logarith-
mic form in order to compare changing viral loads.  A
change from a viral load of 1,000,000 copies/mL to 10,000
copies/mL represents a 2 log reduction in viral load.  Only
changes that are greater than 0.3 to 0.5 log (twofold or
threefold) are considered meaningful in terms of a patient’s
response to medication.
*10,000 copies/mL is presented as a hypothetical baseline
viral load to facilitate comparison of increases and decreas-
es in viral load.
**The Ultrasensitive Viral Load Test can detect viral loads as
low as 50 copies/mL.
Calculating Viral Loads
Viral Copies
Log10
6
5.7
5.3
4.7
4
3.7
3
2.5
2
1
0
1,000,000
500,000
200,000
50,000
10,000
5,000
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400
300
100
50
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0
Log
+2
+1.7
+1.3
+0.7
-0.3
-1
-1.5
-2
Change from Hypothetical Baseline*
Increase
Decrease
Undetectable**
-2
+1
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The New York State Department of Corrections Services (NYS-
DOCS) faces a unique health care challenge: a much higher number
of HIV/AIDS cases than any other state correctional system in the
country (see bar graph of correctional populations). The estimated
number of HIV infected inmates nationally at year end 1996 was
24,881. The NYSDOCS was responsible for 8,700, or 35% of the
nation's HIV infected inmates (1). This was three times higher than
the rate of HIV infection in New Jersey DOC (705 or 3% of the inmate
population), the state with the next highest rate of infected inmates,
and over four times larger than the Florida DOC (2,152 or 3% of the
inmate population). 
Provision of comprehensive HIV care for inmates is a challenge in
any state, but New York faces some special challenges. Four out of
five inmates call the New York City region home but most prisoners
are transferred upstate to one of sixty-nine facilities.  This is far not
only from their homes but also from their past sources of health care,
if they had any, and their future sources of care.  Furthermore, the
NYSDOCS, like most state systems, frequently transfers inmates
among its facilities. There are approximately 650 such transfers
between NY state facilities every day, or 170,000 per year. Keeping
track of medications and medical records during these transfers is a
formidable problem. Continuity of care at the time of release can also
be difficult because of the geographic distance between upstate facil-
ities and post-release locations. 
NYSDOCS in collaboration with the State AIDS Institute has devel-
oped and regularly revises clinical treatment guidelines consistent
with national recommendations to improve continuity of care.
Supplies of medication are sent with inmates on transfer and at
release.  Inmate transfers are tracked by a computer system.  The
NYSDOCS is also evolving toward fully electronic health records.  All
inmates and staff are given annual education in avoiding blood-born
infections.  In a number of prisons, very active Peer Education pro-
grams present the prevention message.
NYSDOCS and the AIDS Institute jointly fund voluntary HIV coun-
seling and testing directly and through community-based organiza-
tions (CBO).  In 1998 over 25,000 voluntary HIV tests were done for
inmates.  The CBO also work with HIV infected inmates on transi-
tional planning so that when released they are already connected
with a continuing source of health care and have been enrolled in
AIDS Drug Assistance (ADAP) programs.
Although faced by these enormous challenges, the absolute number
of AIDS deaths in the NYSDOCS has declined in the past few years,
while the number of AIDS cases has remained quite constant. The
i provement is consistent with but greater than similar improve-
men s in the community.  This probably reflects not only the avail-
ability of newly developed antiretroviral medications both in the com-
munity and inside corrections but also improved care within NYS-
DOCS where health care providers have had HIV-related continuing
education including a unique program developed by Albany Medical
College's Division of HIV Medicine (AMC) and NYSDOCS.  An ongo-
ing series of live satellite-broadcast programs on Management of
HIV/AIDS in the Correctional Setting is downlinked throughout New 
York and to over half of the states (see Save the Dates).  Short term
mini-r sidencies in HIV care are available through AMC.
HIV care is monitored by NYSDOCS regional staff using flow sheets
incorporated in the treatment guidelines.  In addition, NYSDOCS
pharmacists notify care providers if they note apparently inappropri-
ate care (e.g. monotherapy with protease inhibitors).  Programs and
materials to encourage adherence to treatment are developed joint-
ly by AMC and NYSDOCS with ongoing assistance of pharmaceuti-
cal manufacturers.
HIV as well as other specialty care is provided by NYSDOCS through
contracts that must include designated AIDS Treatment Centers.
This assures that specialist consultation is available to inmates wher-
ever they are in the State.  In addition, a network of Regional Medical
Units that provide sub-acute inpatient care within maximum security
perimeters is available.  These units help maintain consistent care
and also reduce cost; they serve as referral hubs.  Half of the pris-
ons are linked by telemedicine equipment and some of the consulta-
tions are being provided through video. According to Dr. Lester
Wrigh , Associate Commissioner/Chief Medical Officer of NYSDOCS,
the improvement in survival and decreases in opportunistic infections
and hospitalization are encouraging, but the potential for rebound as
resistance develops to currently available antiretroviral medications
underscores the importance of ongoing prevention education for
inmates and staff, more effective programs on adherence, and moni-
toring of the care that is given.
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The percentage of men and women who are HIV infected is based upon State and
Federal Prison populations.  These figures represent the number of known cases,
which may be underestimates depending on each state's testing policies, inmate
access to care, etc.  In most prisons, the proportion of HIV infected women is much
higher than HIV infected men.  (Source: Maruschak, Laura. HIV in Prisons and Jails.
Bureau of Justice Statistics. 1998.)
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A report on HIV in the New York Department of Corrections included a table show-
ing this reduction of AIDS deaths and a stabilization in the number of new AIDS
cases. Adapted from the January 8 1999 MMWR Vol. 47/Nos. 51&52.
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A s k  T h e  E x p e r t
W h a t  W o u l d  Y o u  D o ?
Prior to the advent of highly active antiretroviral therapy (HAART), var-
ious manifestations of cytomegalovirus (CMV) infection were fre-
quently seen in HIV positive patients. Because of the difficulties of
establishing a diagnosis of CMV disease and the need for intravenous
therapy once the disease is found, inmates suspected of this diagno-
sis would often require prolonged hospital stays. New pharmacologic
agents and new therapeutic delivery modes have been approved
over the past 3 years to provide clinicians with more than one treat-
ment option for CMV. These treatments provide an alternative to the
long hospital stays by making it possible to treat CMV on an outpa-
tient basis, which is optimal for an infected inmate (1). Even better, it
is now possible, in some cases, to discontinue expensive and com-
plicated therapies if the patients respond to anti-retroviral therapy with
elevations of their CD4 T cell count in excess of 200 cells/cL for
greater than 6 months (for more details, see HEPP News March
1999, archived at www.hivcorrections.org).
One option for both AB and CD is outpatient placement of a PICC line
to enable prolonged intravenous access. I have treated a patient
whose case resembles that of AB. My patient also had esophageal
CMV and an extremely low CD4 T cell count of 0 CD4 T cells/cL. This
intervention makes it possible to give IV ganciclovir in the correction-
al infirmary setting. Within 36 hours of diagnosis, my patient received
his first dose of IV ganciclovir. He had an excellent clinical response
to his HAART, as might patient AB, since they were both anti-retrovi-
ral naïve. His viral load became undetectable, and his CD4 T cell
count stabilized above 200 CD4 T cells/cL for more than 6 months.
Because of this, IV ganciclovir was eventually discontinued. Patient
AB should see the same success. 
Other possible treatments for CMV include ocular implants coupled
with oral ganciclovir (2). This intervention has recently been proven to
effectively prevent systemic recurrence of CMV disease, which was
one of the problems associated with local treatment (ocular implants
without any additional systemic therapy). Alternatively, IV foscarnet
has been preferred to ganciclovir in some clinical settings due to
reports that foscarnet was associated with a survival advantage when
compared to ganciclovir in national randomized control trial (3).
Intravenous cidofovir can be administered via peripheral line at infre-
quent intervals (once every two weeks after the once weekly induc-
tion is completed), which makes it an attractive substitute for ganci-
clovir and foscarnet in some settings. Comparisons to ganciclovir and
foscarnet are underway (4). Renal toxicity is a fairly common side
effect of cidofovir, which can be prevented by the administration of
probenecid (4). Oral ganciclovir is another alternative for maintenance
therapy after IV induction. According to the recent NEJM report, oral
ganciclovir in combination with ocular implantation of a slow release
agent is equally effective as IV induction and maintenance in pre-
venting new cases of CMV.  However, the ganciclovir implant with oral
ganciclovir was substantially more effective than intravenous ganci-
clovir in controlling retinitis.  An additional merit for the implant and oral
treatment is that the patient does not have to suffer the discomfort of
an IV (2). 
Unfortunately, because patient CD has failed his antiretroviral therapy
regimen, he will require long term intravenous ganciclovir.
Furthermore, it is important to consider the realities of providing an IV
treatment in the correctional setting.  In many systems, those with
such devices have limited housing options and therefore suffer limita-
tions on work, schooling, visiting, and so forth.  Additional troubles
arise when a patient is transferred, paroled, or sent out to court.
These limitations can make it very difficult to ensure uninterrupted
intravenous therapy.  Implants and oral ganciclovir, on the other hand,
although more expensive (when the cost of the surgery, implant, and
oral ganciclovir are added up) are very low maintenance and can
enable our patients to avoid treatment interruptions, which may cut
treatment costs in the long run.  For those inmates who fail to seek
medical follow up post parole, the implants also provide a window dur-
ing which a new source of treatment may be identified.
Both of these cases show that even a disease as problematic as CMV
can be successfully evaluated and treated on an outpatient basis in
the prison setting. It requires expertise on the part of prison physicians
to be able to recognize the myriad manifestations of CMV and to
manage the disease once diagnosed. The prison medical team must
be able to access the necessary specialists in as urgent a time frame
as possible. Full cooperation from custody staff is essential in order to
insure that the prisoner is successfully transported to all appoint-
ments.
In the era of effective antiretroviral therapy, the number of opportunis-
tic infections has declined dramatically. However, we must remain
ever vigilant to those patients who will develop opportunistic infec-
tions. Many prisoners are often reluctant to leave their home prison
and may even fear being hospitalized as a strange hospital with unfa-
miliar doctors. The ability to care for a disease such as CMV on an
outpatient basis should help relieve some of the emotional burden
patients will experience when their HIV diseases progress.
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A.B. is a 39 year old African American male, who presented to the correctional facility's acute care hospital with pneumocystis pneumonia as the
initial manifestation of his HIV disease. His initial CD4 count at diagnosis was 0 CD4 T cells/cL, and his RNA PCR viral load was 110,000 copies/mL.
Upon return to general population from the hospital, he was started on HAART therapy with indinavir, stavudine, and lamivudine. Two weeks after
the initiation of antiretroviral therapy, he developed severe dysphagia which failed to respond to empirical therapy with fluconazole, H-2 blockers,
and omperazole. Three weeks after the onset of symptoms, the patient underwent outpatient upper endoscopy. This procedure revealed ulcera-
tions of the esophagus that were typical for CMV; histology confirmed the diagnosis. 
C.D. is a 41 year old African American male, who first presented in 1996 with severe anemia and was found to have disseminated mycobacterium
avium complex (MAC) on bone marrow biopsy. Although his MAC was successfully controlled by his correctional HIV providers with clarithromycin
and ethambutol, virologic control of his HIV disease was never achieved. At a routine clinic visit, he noted that he had been having visual difficul-
ties for several weeks. The consulting ophthalmologist saw the patient on an emergency basis and confirmed the diagnosis of CMV retinitis. 
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Sheree Starrett,  Deputy Director AIDS Services,Correctional Medical Services, New Jersey
Speaker’s Bureau: Bristol-Meyers Squibb, Glaxo-Wellcome, Merck, Roxane.
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March 17, 1999
Bill Would Make HIV Testing Mandatory in Florida Prisons
The Florida Legislature is considering a bill that would require prison
inmates to be tested for HIV, a measure spearheaded by African-
American lawmakers who called it the "No. 1 issue for (the black) cau-
cus."  Co-sponsor state Rep. Tony Hill (D) said the impetus for the meas-
ure was a recent Kaiser Family Foundation study that showed 35% of all
AIDS cases and 43% of new cases occur among blacks. The bill would
mandate testing for inmates within 30 days of arrival at a state prison.
Those who test negative would be tested after 180 days, and again 60
days before being released.  The Wall Street Journal/Southeast Edition
reported that "[t]hose who test positive will be offered treatment," and the
results of the tests will be confidential. County health officials will be noti-
fied if an inmate is released by an emergency court order.  Civil liberties
groups were critical of the measure. (Wall Street Journal/Southeast
Edition, 3/17/99).
April, 1999
Inmates Report Higher Prevalence of Abuse Histories
The Bureau of Justice Statistics recently released data from a study on
sexual abuse among inmate populations entitled Prior Abuse Reported by
Inmates and Probationers. Over a third of the women in the study report-
ed a history of physical or sexual abuse.  More than 36 percent of the
female inmates reported sexual abuse before age 17, which was twice
the rate of child abuse reported by men inmates (15%).  For both male
and female inmates, reports of childhood sexual abuse histories were
twice as high as have been reported for non-incarcerated men and
women.  Male inmates reported sexual abuse by family members most
often, while female inmates reported having experienced sexual abuse by
intimates and family members.  About half or more of incarcerated women
reported their abusers to be current or previous boyfriends or husbands.
A history of abuse was found to be linked to incarceration for sexual
assault or homicide. This report also discusses prevalence of abuse as
related to foster care, single parent households, parental alcohol abuse,
incarcerated relatives, drug and alcohol abuse, and reason for incarcera-
tion. To see the report, go to: http://www.ujp.usdoj/bis/abstract/parip.htm
April, 1999
Injunction Awarded Against Jail for Inadequate HIV Care
On April 16, a federal judge awarded a preliminary injunction in favor of
six HIV-seropositive inmates incarcerated at the Fulton County Jail,
Atl nta, Georgia. The nonprofit Southern Center for Human Rights filed a
law uit on behalf of the inmates on April 9, protesting a recent policy
change where HIV positive jail inmates no longer have access to HIV
expertise at the Grady Hospital. According to the Atlanta Journal-
Constitution, this policy was enacted by the board that oversees Grady
Hospital to address a projected $26 million dollar shortfall in the budget.
Pri r to April of this year, Grady was providing jail inmates with all of their
HIV medications. Approximately 150 inmates housed at the jail are affect-
ed by this change, according to Atlanta lawyer Tamara Serwer, of the
Southern Center for Human Rights. Among the defendants in the lawsuit
are the members of the Fulton County Commission, a group of legislators
who oversee the jail's budget.
April 29, 1999
As first reported in last month’s HEPP News...
Discontinuation of Primary PCP Prophylaxis Studied
In two articles published in the New England Journal of Medicine,inves-
tigators at two research centers concluded that stopping primary PCP
prophyslaxis was safe in HIV patients who are receiving antiretroviral
therapy and who have sustained CD4 counts of at least 200 cells/cubic
meter and to a minimum of 14 percent of total lymphocytes for a pro-
longed period of time (at least six months in most cases). 
This recommendation is not yet official and the benefit of stopping one
daily pill must be weighed against the risk of losing the protective effect
that same pill has against other opportunistic infections (toxoplasmosis). 
The two articles from the April 29, 1999 publication can be found online
at: http://www.nejm.org/content/index.asp. The references are: Furrer H,
Egger M, Opravil M et al. Discontinuation of Primary Prophylaxis Against
Pneumocystis Carinii Pneumonia in HIV-1-Infected Adults Treated With
Combination Antiretroviral Therapy. NEJM, 340 (17) 1301; and Masur H,
Kaplan J. Does Pneumocystis Carinii Prophylaxis Still Need to Be
Lifelong? NEJM 340 (17) 1356.
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WEBSITES:
The Bureau of Justice Statistics
http://www.ojp.usdoj.gov/bjs/
CDC HIV/AIDS Statistics
http://www.cdc.gov/nchstp/hiv_aids/stats/hasr1001.pdf
The Corrections Connection
http://www.corrections.com
The 6th Conference on Retroviruses & Opportunistic Infections
(homepage)
http://www.retroconference.org/99/
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Self-Assessment Test for Continuing Medical Education Credit
Brown University School of Medicine designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s
Recognition Award.  To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each
of the questions. A minimum of 70% of the questions must be answered correctly.  This activity is eligible for CME credit through July
15, 1999.  The estimated time for completion of this activity is one hour and there is no fee for participation in this activity.
Indicate whether the following statements are true or false:
1. CMV can be treated while the patient is in the general
population. 
True False
2. Both a woman and a man with a CD4 count of 350 and
a viral load of 20,000 copies will progress to AIDS within
the same time period. 
True False
3. According to a recent NEJM report, oral ganciclovir in
combination with ocular implantation of a slow release
agent is equally effective as IV induction and maintenance
in controling retinitis.
True False
4. The use of HAART  has increased the overall cost of
HIV care.
True False
5. Prisons and jails may be providing care for approxi-
mately one tenth of the number of HIV infected individuals
that are accessing care outside of corrections. 
True False
6. A change in viral load of 0.2 logs implies a significant
response to HIV medication. 
True False
7. Progression to AIDS can be extrapolated given data
points covering about 6 months. 
True False
8. Studies of blood donors revealed what new finding?
a) Many blood donors are aware of their HIV risk  
b) Incidence of HIV infection among blood donors 
is much higher than among incarcerated persons 
c) New types of HIV (other clades ) may be entering 
the US 
d) HIV incidence among blood donors is highest in 
the North East 
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The Brown University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) sponsor continuing
medical education activities for physicians.  Each physician should claim only those hours of credit that he/she actually spent in the educational activi-
ty.  This activity has been planned and implemented in accordance with the Essentials and Standards of the ACCME.
The use of the Brown University School of Medicine name implies review of the educational format and material only.  The opinions, recommendations
and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the Brown
University School of Medicine.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660
Be sure to print clearly so that we have the correct information for you.
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HEPP News Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1   
Case Study 5  4  3  2  1   5  4  3  2  1   
HEPPigram 5  4  3  2  1   5  4  3  2  1   
News Flashes 5  4  3  2  1   5  4  3  2  1   
Save the Dates5  4  3  2  1   5  4  3  2  1   
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPPNews be made more useful to you?
